Logo image of 1SRPT.MI

SAREPTA THERAPEUTICS INC (1SRPT.MI) Stock Fundamental Analysis

Europe - BIT:1SRPT - US8036071004 - Common Stock

19.125 EUR
+3.71 (+24.03%)
Last: 10/3/2025, 7:00:00 PM
Fundamental Rating

3

1SRPT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 73 industry peers in the Biotechnology industry. 1SRPT may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, 1SRPT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year 1SRPT has reported negative net income.
In the past year 1SRPT has reported a negative cash flow from operations.
1SRPT had negative earnings in 4 of the past 5 years.
1SRPT had negative operating cash flow in 4 of the past 5 years.
1SRPT.MI Yearly Net Income VS EBIT VS OCF VS FCF1SRPT.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M -600M

1.2 Ratios

With a decent Return On Assets value of -1.57%, 1SRPT is doing good in the industry, outperforming 72.60% of the companies in the same industry.
1SRPT has a Return On Equity of -4.27%. This is in the better half of the industry: 1SRPT outperforms 73.97% of its industry peers.
Industry RankSector Rank
ROA -1.57%
ROE -4.27%
ROIC N/A
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
1SRPT.MI Yearly ROA, ROE, ROIC1SRPT.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

Looking at the Gross Margin, with a value of 79.28%, 1SRPT is in the better half of the industry, outperforming 76.71% of the companies in the same industry.
In the last couple of years the Gross Margin of 1SRPT has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for 1SRPT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 79.28%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
1SRPT.MI Yearly Profit, Operating, Gross Margins1SRPT.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

3

2. Health

2.1 Basic Checks

1SRPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, 1SRPT has more shares outstanding
The number of shares outstanding for 1SRPT has been increased compared to 5 years ago.
Compared to 1 year ago, 1SRPT has an improved debt to assets ratio.
1SRPT.MI Yearly Shares Outstanding1SRPT.MI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
1SRPT.MI Yearly Total Debt VS Total Assets1SRPT.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

Based on the Altman-Z score of 0.15, we must say that 1SRPT is in the distress zone and has some risk of bankruptcy.
1SRPT has a Altman-Z score (0.15) which is in line with its industry peers.
1SRPT has a Debt/Equity ratio of 0.84. This is a neutral value indicating 1SRPT is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.84, 1SRPT perfoms like the industry average, outperforming 45.21% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.84
Debt/FCF N/A
Altman-Z 0.15
ROIC/WACCN/A
WACC7.87%
1SRPT.MI Yearly LT Debt VS Equity VS FCF1SRPT.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B

2.3 Liquidity

1SRPT has a Current Ratio of 2.89. This indicates that 1SRPT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.89, 1SRPT is in the better half of the industry, outperforming 63.01% of the companies in the same industry.
A Quick Ratio of 1.81 indicates that 1SRPT should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.81, 1SRPT perfoms like the industry average, outperforming 53.42% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.89
Quick Ratio 1.81
1SRPT.MI Yearly Current Assets VS Current Liabilites1SRPT.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

4

3. Growth

3.1 Past

1SRPT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -293.33%.
The Revenue has grown by 64.89% in the past year. This is a very strong growth!
1SRPT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.94% yearly.
EPS 1Y (TTM)-293.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2600%
Revenue 1Y (TTM)64.89%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%68.38%

3.2 Future

The Earnings Per Share is expected to grow by 7.30% on average over the next years.
The Revenue is expected to decrease by -5.18% on average over the next years.
EPS Next Y-296.75%
EPS Next 2Y1.05%
EPS Next 3Y-4.56%
EPS Next 5Y7.3%
Revenue Next Year9.01%
Revenue Next 2Y-8.25%
Revenue Next 3Y-8.68%
Revenue Next 5Y-5.18%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
1SRPT.MI Yearly Revenue VS Estimates1SRPT.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
1SRPT.MI Yearly EPS VS Estimates1SRPT.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 -4 -6 -8

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

1SRPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 9.59, which indicates a very decent valuation of 1SRPT.
Compared to the rest of the industry, the Price/Forward Earnings ratio of 1SRPT indicates a rather cheap valuation: 1SRPT is cheaper than 93.15% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of 1SRPT to the average of the S&P500 Index (23.36), we can say 1SRPT is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 9.59
1SRPT.MI Price Earnings VS Forward Price Earnings1SRPT.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

1SRPT's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. 1SRPT is cheaper than 75.34% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 59.47
1SRPT.MI Per share data1SRPT.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

A cheap valuation may be justified as 1SRPT's earnings are expected to decrease with -4.56% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.05%
EPS Next 3Y-4.56%

More info and screens

0

5. Dividend

5.1 Amount

1SRPT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SAREPTA THERAPEUTICS INC

BIT:1SRPT (10/3/2025, 7:00:00 PM)

19.125

+3.71 (+24.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)10-29 2025-10-29/amc
Inst Owners81.76%
Inst Owner ChangeN/A
Ins Owners4.63%
Ins Owner ChangeN/A
Market Cap2.00B
Analysts67.43
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-114.71%
Min EPS beat(2)-376.26%
Max EPS beat(2)146.84%
EPS beat(4)2
Avg EPS beat(4)24.21%
Min EPS beat(4)-376.26%
Max EPS beat(4)348.76%
EPS beat(8)6
Avg EPS beat(8)617.4%
EPS beat(12)8
Avg EPS beat(12)384.79%
EPS beat(16)10
Avg EPS beat(16)285.72%
Revenue beat(2)2
Avg Revenue beat(2)9.95%
Min Revenue beat(2)6.86%
Max Revenue beat(2)13.04%
Revenue beat(4)4
Avg Revenue beat(4)8.67%
Min Revenue beat(4)2.86%
Max Revenue beat(4)13.04%
Revenue beat(8)7
Avg Revenue beat(8)5.95%
Revenue beat(12)9
Avg Revenue beat(12)3.94%
Revenue beat(16)12
Avg Revenue beat(16)3.6%
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)-13.65%
EPS NQ rev (3m)-208.37%
EPS NY rev (1m)5.93%
EPS NY rev (3m)-74.63%
Revenue NQ rev (1m)-5.69%
Revenue NQ rev (3m)-45.85%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-13.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 9.59
P/S 0.94
P/FCF N/A
P/OCF N/A
P/B 1.72
P/tB 1.76
EV/EBITDA 59.47
EPS(TTM)-0.74
EYN/A
EPS(NY)1.99
Fwd EY10.42%
FCF(TTM)-3.71
FCFYN/A
OCF(TTM)-2.46
OCFYN/A
SpS20.3
BVpS11.1
TBVpS10.86
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.57%
ROE -4.27%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 79.28%
FCFM N/A
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
F-Score2
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 0.84
Debt/FCF N/A
Debt/EBITDA 28.38
Cap/Depr 372.98%
Cap/Sales 6.17%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.89
Quick Ratio 1.81
Altman-Z 0.15
F-Score2
WACC7.87%
ROIC/WACCN/A
Cap/Depr(3y)221.92%
Cap/Depr(5y)219.29%
Cap/Sales(3y)6.11%
Cap/Sales(5y)8.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-293.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2600%
EPS Next Y-296.75%
EPS Next 2Y1.05%
EPS Next 3Y-4.56%
EPS Next 5Y7.3%
Revenue 1Y (TTM)64.89%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%68.38%
Revenue Next Year9.01%
Revenue Next 2Y-8.25%
Revenue Next 3Y-8.68%
Revenue Next 5Y-5.18%
EBIT growth 1Y-102.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-229.84%
EBIT Next 3Y13.2%
EBIT Next 5Y10.53%
FCF growth 1Y15.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.48%
OCF growth 3YN/A
OCF growth 5YN/A